Detalles de la búsqueda
1.
Pharmacological characterization of mutant huntingtin aggregate-directed PET imaging tracer candidates.
Sci Rep
; 11(1): 17977, 2021 09 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34504195
2.
[11C]CHDI-626, a PET Tracer Candidate for Imaging Mutant Huntingtin Aggregates with Reduced Binding to AD Pathological Proteins.
J Med Chem
; 64(16): 12003-12021, 2021 08 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-34351166
3.
Improved synthesis of [18F] fallypride and characterization of a Huntington's disease mouse model, zQ175DN KI, using longitudinal PET imaging of D2/D3 receptors.
EJNMMI Radiopharm Chem
; 4(1): 20, 2019 Aug 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31659519
4.
Noninvasive Relative Quantification of [11C]ABP688 PET Imaging in Mice Versus an Input Function Measured Over an Arteriovenous Shunt.
Front Neurol
; 9: 516, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30013509
5.
MR-based spatial normalization improves [18F]MNI-659 PET regional quantification and detectability of disease effect in the Q175 mouse model of Huntington's disease.
PLoS One
; 13(10): e0206613, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30365550
6.
Quantifying autophagy using novel LC3B and p62 TR-FRET assays.
PLoS One
; 13(3): e0194423, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29554128
7.
Longitudinal Characterization of mGluR5 Using 11C-ABP688 PET Imaging in the Q175 Mouse Model of Huntington Disease.
J Nucl Med
; 59(11): 1722-1727, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-29794227
8.
N-Acylthiadiazolines, a new class of liver X receptor agonists with selectivity for LXRbeta.
J Med Chem
; 50(17): 4255-9, 2007 Aug 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-17665897
9.
Longitudinal Small-Animal PET Imaging of the zQ175 Mouse Model of Huntington Disease Shows In Vivo Changes of Molecular Targets in the Striatum and Cerebral Cortex.
J Nucl Med
; 58(4): 617-622, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-27856625
10.
2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor.
J Med Chem
; 49(23): 6819-32, 2006 Nov 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-17154512
11.
5-Cyanopyrimidine derivatives as a novel class of potent, selective, and orally active inhibitors of p38alpha MAP kinase.
J Med Chem
; 48(20): 6261-70, 2005 Oct 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-16190753
12.
Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntington's disease.
J Med Chem
; 58(3): 1159-83, 2015 Feb 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-25590515
13.
Lead optimization toward proof-of-concept tools for Huntington's disease within a 4-(1H-pyrazol-4-yl)pyrimidine class of pan-JNK inhibitors.
J Med Chem
; 58(7): 2967-87, 2015 Apr 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-25760409
14.
Imidazoquinoxaline Src-family kinase p56Lck inhibitors: SAR, QSAR, and the discovery of (S)-N-(2-chloro-6-methylphenyl)-2-(3-methyl-1-piperazinyl)imidazo- [1,5-a]pyrido[3,2-e]pyrazin-6-amine (BMS-279700) as a potent and orally active inhibitor with excellent in vivo antiinflammatory activity.
J Med Chem
; 47(18): 4517-29, 2004 Aug 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-15317463
15.
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
J Med Chem
; 47(27): 6658-61, 2004 Dec 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-15615512
16.
The discovery of orally active triaminotriazine aniline amides as inhibitors of p38 MAP kinase.
J Med Chem
; 47(25): 6283-91, 2004 Dec 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-15566298
17.
A monoclonal antibody TrkB receptor agonist as a potential therapeutic for Huntington's disease.
PLoS One
; 9(2): e87923, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24503862
18.
SAR Development of Lysine-Based Irreversible Inhibitors of Transglutaminase 2 for Huntington's Disease.
ACS Med Chem Lett
; 3(12): 1024-8, 2012 Dec 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-24900424
19.
Irreversible 4-Aminopiperidine Transglutaminase 2 Inhibitors for Huntington's Disease.
ACS Med Chem Lett
; 3(9): 731-5, 2012 Sep 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-24900540
20.
Discovery and structure-activity relationship of potent and selective covalent inhibitors of transglutaminase 2 for Huntington's disease.
J Med Chem
; 55(3): 1021-46, 2012 Feb 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-22224594